Adlon Therapeutics L.P. Announces Publication of Data from Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Studies Examining Sleep Quality Outcomes in CNS Drugs
Adlon Therapeutics L.P. Announces Two New Publications of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Data
Adlon Therapeutics L.P. and the Prescription Drug Safety Network Launch New Resources to Encourage Safe and Responsible Use of Prescription Stimulant Medications
Adlon Therapeutics L.P. Announces Publication of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Study Data in the Journal of Attention Disorders
Adlon Therapeutics Secures Adhansia XR™ (methylphenidate HCI) Extended Release Capsules CII Formulary Coverage from Express Scripts
Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting
Adlon Therapeutics L.P. and Purdue Pharma L.P. to Present Six Scientific Posters at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting
Adhansia XR™ (methylphenidate HCl) Extended Release Capsules CII, New ADHD Treatment from Adlon Therapeutics L.P., Now Available Throughout the U.S.
Christian Mazzi, MD, BSBA/BA, MBA Named President and Executive Medical Director, Adlon Therapeutics L.P.
Adlon Therapeutics L.P. Joins the Prescription Drug Safety Network
- 1
- 2